$6.56
-0.34-4.93%
Pre-Market: 8:00 AM EDT
15 minutes delayed
Bioventus
BVSNASDAQ
Bioventus (NASDAQ:BVS) Stock, Analyst Ratings, Price Targets, Forecasts
Bioventus Inc has a consensus price target of $6.13 based on the ratings of 6 analysts. The high is $9 issued by Craig-Hallum on March 13, 2024. The low is $2.5 issued by Goldman Sachs on November 30, 2022. The 3 most-recent analyst ratings were released by Canaccord Genuity, Craig-Hallum, and Canaccord Genuity on May 8, 2024, March 13, 2024, and December 7, 2023, respectively. With an average price target of $8 between Canaccord Genuity, Craig-Hallum, and Canaccord Genuity, there's an implied 21.95% upside for Bioventus Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Craig-Hallum
Goldman Sachs
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Bioventus
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 21.95% | Canaccord Genuity | William Plovanic | $7 → $8 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | 37.2% | Craig-Hallum | Alexander Nowak | $6 → $9 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | 6.71% | Canaccord Genuity | William Plovanic | $3.66 → $7 | Upgrade | Hold → Buy | Get Alert |
| 04/03/2023 | Buy Now | -23.78% | Craig-Hallum | Alexander Nowak | $10 → $5 | Maintains | Hold | Get Alert |
| 11/30/2022 | Buy Now | -61.89% | Goldman Sachs | Amit Hazan | $13 → $2.5 | Maintains | Neutral | Get Alert |
| 11/22/2022 | Buy Now | — | Craig-Hallum | Alexander Nowak | — | Downgrade | Buy → Hold | Get Alert |
| 11/10/2022 | Buy Now | -23.78% | Morgan Stanley | Drew Ranieri | $11 → $5 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | — | Canaccord Genuity | Kyle Rose | — | Downgrade | Buy → Hold | Get Alert |
| 11/09/2022 | Buy Now | — | JP Morgan | Robbie Marcus | — | Downgrade | Overweight → Underweight | Get Alert |
| 10/11/2022 | Buy Now | 67.68% | Morgan Stanley | Drew Ranieri | $12 → $11 | Maintains | Overweight | Get Alert |
| 09/07/2022 | Buy Now | 98.17% | Goldman Sachs | Amit Hazan | $15 → $13 | Maintains | Neutral | Get Alert |
| 08/12/2022 | Buy Now | 82.93% | Morgan Stanley | Drew Ranieri | $11 → $12 | Maintains | Overweight | Get Alert |
| 05/12/2022 | Buy Now | 67.68% | Morgan Stanley | Drew Ranieri | $18 → $11 | Maintains | Overweight | Get Alert |
| 03/21/2022 | Buy Now | 159.15% | Goldman Sachs | Amit Hazan | $19 → $17 | Maintains | Neutral | Get Alert |
| 03/15/2022 | Buy Now | 357.32% | Craig-Hallum | Alexander Nowak | → $30 | Initiates | → Buy | Get Alert |
| 03/11/2022 | Buy Now | 174.39% | Morgan Stanley | Drew Ranieri | $20 → $18 | Maintains | Overweight | Get Alert |
| 11/15/2021 | Buy Now | 204.88% | Morgan Stanley | Drew Ranieri | — | Reinstates | → Overweight | Get Alert |
FAQ
What is the target price for Bioventus (BVS) stock?
The latest price target for Bioventus (NASDAQ:BVS) was reported by Canaccord Genuity on May 8, 2024. The analyst firm set a price target for $8.00 expecting BVS to rise to within 12 months (a possible 21.95% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bioventus (BVS)?
The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by Canaccord Genuity, and Bioventus maintained their buy rating.
When was the last upgrade for Bioventus (BVS)?
The last upgrade for Bioventus Inc happened on December 7, 2023 when Canaccord Genuity raised their price target to $7. Canaccord Genuity previously had a hold for Bioventus Inc.
When was the last downgrade for Bioventus (BVS)?
The last downgrade for Bioventus Inc happened on November 22, 2022 when Craig-Hallum changed their price target from N/A to N/A for Bioventus Inc.
When is the next analyst rating going to be posted or updated for Bioventus (BVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Bioventus (BVS) correct?
While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $7.00 to $8.00. The current price Bioventus (BVS) is trading at is $6.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.